Loading...

We've got a brand new version of Simply Wall St! Try it out

Benitec Biopharma

ASX:BLT
Snowflake Description

Flawless balance sheet and undervalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BLT
ASX
A$17M
Market Cap
  1. Home
  2. AU
  3. Pharmaceuticals & Biotech
Company description

Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The last earnings update was 81 days ago. More info.


Add to Portfolio Compare Print
  • Benitec Biopharma has significant price volatility in the past 3 months.
BLT Share Price and Events
7 Day Returns
10.2%
ASX:BLT
4.7%
AU Biotechs
0.9%
AU Market
1 Year Returns
-65.2%
ASX:BLT
50.9%
AU Biotechs
16.3%
AU Market
BLT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Benitec Biopharma (BLT) 10.2% 1.9% 1.9% -65.2% -50.9% -92.7%
AU Biotechs 4.7% 8.7% 20% 50.9% 168.8% 226.4%
AU Market 0.9% 1.9% 5.1% 16.3% 22.3% 22.5%
1 Year Return vs Industry and Market
  • BLT underperformed the Biotechs industry which returned 50.9% over the past year.
  • BLT underperformed the Market in Australia which returned 16.3% over the past year.
Price Volatility
BLT
Industry
5yr Volatility vs Market

Value

 Is Benitec Biopharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Benitec Biopharma to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Benitec Biopharma.

ASX:BLT Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 9.4%
Perpetual Growth Rate 10-Year AU Government Bond Rate 2.3%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for ASX:BLT
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year AU Govt Bond Rate 2.3%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.28
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.28 (1 + (1- 30%) (0%))
1.188
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.19
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.31% + (1.188 * 5.96%)
9.39%

Discounted Cash Flow Calculation for ASX:BLT using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Benitec Biopharma is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

ASX:BLT DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (AUD, Millions) Source Present Value
Discounted (@ 9.39%)
2020 8.80 Est @ 62.24% 8.04
2021 12.69 Est @ 44.26% 10.60
2022 16.71 Est @ 31.68% 12.77
2023 20.53 Est @ 22.87% 14.34
2024 23.96 Est @ 16.7% 15.30
2025 26.93 Est @ 12.38% 15.71
2026 29.45 Est @ 9.36% 15.71
2027 31.58 Est @ 7.25% 15.40
2028 33.40 Est @ 5.77% 14.89
2029 34.98 Est @ 4.73% 14.26
Present value of next 10 years cash flows A$137.00
ASX:BLT DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= A$34.98 × (1 + 2.31%) ÷ (9.39% – 2.31%)
A$505.59
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= A$505.59 ÷ (1 + 9.39%)10
A$206.04
ASX:BLT Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= A$137.00 + A$206.04
A$343.04
Equity Value per Share
(AUD)
= Total value / Shares Outstanding
= A$343.04 / 313.03
A$1.1
ASX:BLT Discount to Share Price
Calculation Result
Value per share (AUD) From above. A$1.10
Current discount Discount to share price of A$0.05
= -1 x (A$0.05 - A$1.10) / A$1.10
95.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Benitec Biopharma is available for.
Intrinsic value
>50%
Share price is A$0.05 vs Future cash flow value of A$1.1
Current Discount Checks
For Benitec Biopharma to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Benitec Biopharma's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Benitec Biopharma's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Benitec Biopharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Benitec Biopharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:BLT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in AUD A$0.02
ASX:BLT Share Price ** ASX (2019-11-17) in AUD A$0.05
Global Biotechs Industry PE Ratio Median Figure of 145 Publicly-Listed Biotechs Companies 30.8x
Australia Market PE Ratio Median Figure of 519 Publicly-Listed Companies 18.63x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Benitec Biopharma.

ASX:BLT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:BLT Share Price ÷ EPS (both in AUD)

= 0.05 ÷ 0.02

3.39x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Benitec Biopharma is good value based on earnings compared to the Global Biotechs industry average.
  • Benitec Biopharma is good value based on earnings compared to the Australia market.
Price based on expected Growth
Does Benitec Biopharma's expected growth come at a high price?
Raw Data
ASX:BLT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 3.39x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Global Biotechs Industry PEG Ratio Median Figure of 85 Publicly-Listed Biotechs Companies 1.39x
Australia Market PEG Ratio Median Figure of 347 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Benitec Biopharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Benitec Biopharma's assets?
Raw Data
ASX:BLT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in AUD A$0.09
ASX:BLT Share Price * ASX (2019-11-17) in AUD A$0.05
Australia Biotechs Industry PB Ratio Median Figure of 38 Publicly-Listed Biotechs Companies 3.17x
Australia Market PB Ratio Median Figure of 1,584 Publicly-Listed Companies 1.75x
ASX:BLT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:BLT Share Price ÷ Book Value per Share (both in AUD)

= 0.05 ÷ 0.09

0.59x

* Primary Listing of Benitec Biopharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Benitec Biopharma is good value based on assets compared to the AU Biotechs industry average.
X
Value checks
We assess Benitec Biopharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Benitec Biopharma has a total score of 5/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Benitec Biopharma expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Benitec Biopharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Benitec Biopharma expected to grow at an attractive rate?
  • Unable to compare Benitec Biopharma's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Benitec Biopharma's earnings growth to the Australia market average as no estimate data is available.
  • Unable to compare Benitec Biopharma's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ASX:BLT Future Growth Rates Data Sources
Data Point Source Value (per year)
Australia Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 13%
Australia Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 10.3%
Australia Market Earnings Growth Rate Market Cap Weighted Average 9.7%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:BLT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:BLT Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2019-06-30 17 6 4
2019-03-31 17 3 4
2018-12-31 18 3 3
2018-09-30 11 -4 -4
2018-06-30 4 -10 -12
2018-03-31 5 -9 -11
2017-12-31 7 -7 -9
2017-09-30 6 -6 -9
2017-06-30 11 -8 -6
2017-03-31 10 -8 -9
2016-12-31 10 -14 -12
2016-09-30 10 -18 -15

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Benitec Biopharma is high growth as no earnings estimate data is available.
  • Unable to determine if Benitec Biopharma is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:BLT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Benitec Biopharma Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:BLT Past Financials Data
Date (Data in AUD Millions) EPS *
2019-06-30 0.02
2019-03-31 0.01
2018-12-31 0.01
2018-09-30 -0.02
2018-06-30 -0.06
2018-03-31 -0.05
2017-12-31 -0.04
2017-09-30 -0.05
2017-06-30 -0.03
2017-03-31 -0.06
2016-12-31 -0.08
2016-09-30 -0.10

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Benitec Biopharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine whether Benitec Biopharma is trading at Benitec Biopharma'san attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  2. Benitec Biopharma's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Benitec Biopharma's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Benitec Biopharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Benitec Biopharma has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Benitec Biopharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Benitec Biopharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Benitec Biopharma has delivered over 20% year on year earnings growth in the past 5 years.
  • Benitec Biopharma has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • Benitec Biopharma has become profitable in the last year making it difficult to compare the Global Biotechs industry average.
Earnings and Revenue History
Benitec Biopharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Benitec Biopharma Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:BLT Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 17.07 4.09 9.51 3.10
2019-03-31 17.11 3.54 9.41 4.40
2018-12-31 17.72 3.23 9.28 5.25
2018-09-30 11.42 -4.23 8.96 6.31
2018-06-30 4.38 -11.64 8.73 6.89
2018-03-31 4.82 -11.18 8.64 6.50
2017-12-31 7.42 -8.54 8.66 6.22
2017-09-30 6.19 -9.31 9.10 5.81
2017-06-30 11.09 -5.69 9.10 6.93
2017-03-31 9.82 -9.37 9.14 7.48
2016-12-31 9.66 -11.67 9.51 9.14
2016-09-30 9.61 -15.34 11.20 9.74
2016-06-30 4.05 -24.78 11.71 13.29
2016-03-31 4.42 -23.76 12.08 13.15
2015-12-31 3.08 -22.54 11.26 12.17
2015-09-30 3.31 -17.68 8.93 11.19
2015-06-30 3.40 -11.51 8.14 6.23
2015-03-31 3.54 -8.12 6.89 5.13
2014-12-31 1.79 -8.72 6.43 4.12
2014-09-30 1.58 -7.88 5.62 3.94
2014-06-30 1.37 -7.04 4.81 3.76
2014-03-31 1.23 -5.16 4.39 3.04
2013-12-31 1.09 -3.29 3.97 2.32
2013-09-30 1.28 -3.39 3.78 1.80
2013-06-30 1.46 -3.49 3.59 1.28
2013-03-31 1.18 -4.46 3.31 1.48
2012-12-31 0.90 -5.43 3.04 1.68

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Benitec Biopharma has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Benitec Biopharma used its assets more efficiently than the Global Biotechs industry average last year based on Return on Assets.
  • Benitec Biopharma has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess Benitec Biopharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Benitec Biopharma has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Benitec Biopharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Benitec Biopharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Benitec Biopharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Benitec Biopharma has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Benitec Biopharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Benitec Biopharma has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Benitec Biopharma Company Filings, last reported 4 months ago.

ASX:BLT Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 23.66 0.00 22.41
2019-03-31 23.66 0.00 22.41
2018-12-31 28.11 0.00 23.19
2018-09-30 28.11 0.00 23.19
2018-06-30 18.74 0.00 16.12
2018-03-31 13.20 0.00 10.58
2017-12-31 15.93 0.00 10.34
2017-09-30 18.78 0.00 14.80
2017-06-30 21.51 0.00 17.38
2017-03-31 23.98 0.00 19.72
2016-12-31 18.55 0.00 12.37
2016-09-30 19.74 0.00 13.39
2016-06-30 18.84 0.00 18.26
2016-03-31 24.84 0.00 19.88
2015-12-31 27.29 0.00 24.76
2015-09-30 23.88 0.00 21.79
2015-06-30 23.88 0.00 21.79
2015-03-31
2014-12-31 29.62 0.00 26.83
2014-09-30 29.62 0.00 26.83
2014-06-30 33.54 0.00 31.36
2014-03-31 33.54 0.00 31.36
2013-12-31 7.69 0.00 5.18
2013-09-30 7.69 0.00 5.18
2013-06-30 0.64 0.00 1.59
2013-03-31 0.64 0.00 1.59
2012-12-31 0.59 0.00 1.21
  • Benitec Biopharma has no debt.
  • Benitec Biopharma has not taken on any debt in the past 5 years.
  • Benitec Biopharma has no debt, it does not need to be covered by operating cash flow.
  • Benitec Biopharma has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Benitec Biopharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Benitec Biopharma has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Benitec Biopharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Benitec Biopharma dividends.
If you bought A$2,000 of Benitec Biopharma shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Benitec Biopharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Benitec Biopharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:BLT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 59 Stocks 2.1%
Australia Market Average Dividend Yield Market Cap Weighted Average of 390 Stocks 4%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.5%
Australia Bottom 25% Dividend Yield 25th Percentile 2.4%
Australia Top 25% Dividend Yield 75th Percentile 5.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Benitec Biopharma has not reported any payouts.
  • Unable to verify if Benitec Biopharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Benitec Biopharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Benitec Biopharma has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Benitec Biopharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Benitec Biopharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Benitec Biopharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Benitec Biopharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jerel Banks
COMPENSATION A$1,293,248
TENURE AS CEO 1.4 years
CEO Bio

Dr. Jerel A. Banks, Ph.D., M.D. has been Chief Executive Officer of Benitec Biopharma Limited since June 26, 2018. Dr. Banks serves as Chief Investment Officer of NantVentures. Dr. Banks has been Senior Vice President of Mergers and Acquisitions at NantKwest, Inc. since September 22, 2015. Dr. Banks serves as a Vice President, Portfolio Manager and Research Analyst at Franklin Advisers, Inc. Dr. Banks serves as Vice President, Portfolio Manager and Research Analyst at Franklin Templeton Investments. Dr. Banks served as Portfolio Manager and Research Analyst at Franklin Templeton Investment Funds SICAV - Franklin Biotechnology Discovery Fund and Franklin Strategic Series - Franklin Biotechnology Discovery Fund. Dr. Banks joined Franklin Templeton Investments in 2012. Previously, Dr. Banks served as a Senior Equity Research Analyst covering the biotechnology sector and Financial Analyst at Sectoral Asset Management Inc., and Apothecary Capital. Dr. Banks served as an Equity Research Associate on the healthcare investment team at Capital Research and Management. Dr. Banks serves as the Executive Chairman of the Board at Benitec Biopharma Limited since June 15, 2018 and served as its Chairman of the Board from October 12, 2017 to June 15, 2018. Dr. Banks served as a Non-Executive Director of Benitec Biopharma Limited from October 26, 2016 to June 15, 2018. Dr. Banks received an M.D. and Ph.D. in Organic Chemistry from Brown University and holds a B.A. in Chemistry from Princeton University.

CEO Compensation
  • Jerel's compensation has increased in line with Benitec Biopharma recently becoming profitable.
  • Jerel's remuneration is higher than average for companies of similar size in Australia.
Management Team Tenure

Average tenure of the Benitec Biopharma management team in years:

2.3
Average Tenure
  • The tenure for the Benitec Biopharma management team is about average.
Management Team

Jerel Banks

TITLE
CEO & Executive Chairman
COMPENSATION
A$1M
TENURE
1.4 yrs

Megan Boston

TITLE
Head of Operations - Australia & Executive Director
COMPENSATION
A$394K
TENURE
1.4 yrs

Bryan Dulhunty

TITLE
Chief Financial Officer
TENURE
3.3 yrs

Michael Graham

TITLE
Head of Discovery & Founding Scientist
COMPENSATION
A$217K
TENURE
4.4 yrs

Craig Lewis

TITLE
Chief Medical Adviser
TENURE
5.7 yrs

Claudia Kloth

TITLE
Senior Vice President of Manufacturing

Oliver Kidd

TITLE
Company Secretary
TENURE
1.4 yrs
Board of Directors Tenure

Average tenure of the Benitec Biopharma board of directors in years:

4.1
Average Tenure
  • The tenure for the Benitec Biopharma board of directors is about average.
Board of Directors

Megan Boston

TITLE
Head of Operations - Australia & Executive Director
COMPENSATION
A$394K
TENURE
3.3 yrs

Peter Francis

TITLE
Non-Executive Director
COMPENSATION
A$77K
AGE
63
TENURE
13.8 yrs

Jerel Banks

TITLE
CEO & Executive Chairman
COMPENSATION
A$1M
TENURE
1.4 yrs

J. Buchi

TITLE
Non-Executive Director
COMPENSATION
A$77K
TENURE
6.6 yrs

Geoffrey McCaughan

TITLE
Member of Hepatology Clinical Advisory Board
TENURE
4.1 yrs

Harry Janssen

TITLE
Member of Hepatology Clinical Advisory Board
TENURE
4.1 yrs

Keyur Patel

TITLE
Member of Hepatology Clinical Advisory Board
TENURE
4.1 yrs

George Dickson

TITLE
Member of Scientific & Clinical Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
X
Management checks
We assess Benitec Biopharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Benitec Biopharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Why Fundamental Investors Might Love Benitec Biopharma Limited (ASX:BLT)

By this I mean, I look at stocks holistically, from their financial health to their future outlook. … In the case of Benitec Biopharma Limited (ASX:BLT), it is a company that has been able to sustain great financial health, trading at an attractive share price. … ASX:BLT Price Estimation Relative to Market, July 20th 2019 Next Steps: For Benitec Biopharma, there are three fundamental factors you should further examine: Future Outlook: What are well-informed industry analysts predicting for BLT’s future growth?

Simply Wall St -

Can We See Significant Institutional Ownership On The Benitec Biopharma Limited (ASX:BLT) Share Register?

View our latest analysis for Benitec Biopharma ASX:BLT Ownership Summary, June 19th 2019 What Does The Institutional Ownership Tell Us About Benitec Biopharma? … Insider Ownership Of Benitec Biopharma While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. … But other times, private equity is selling out, having taking the company public.

Simply Wall St -

Imagine Owning Benitec Biopharma (ASX:BLT) And Trying To Stomach The 90% Share Price Drop

Spare a thought for those who held Benitec Biopharma Limited (ASX:BLT) for five whole years - as the share price tanked 90%. … See our latest analysis for Benitec Biopharma To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. … One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.

Simply Wall St -

Benitec Biopharma Limited (ASX:BLT) Delivered A Weaker ROE Than Its Industry

By way of learning-by-doing, we'll look at ROE to gain a better understanding of Benitec Biopharma Limited (ASX:BLT). … That means that for every A$1 worth of shareholders' equity, it generated A$0.12 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

These Fundamentals Make Benitec Biopharma Limited (ASX:BLT) Truly Worth Looking At

In the case of Benitec Biopharma Limited (ASX:BLT), there's. … is a company that has been able to sustain great financial health, trading at an attractive share price. … report on Benitec Biopharma here

Simply Wall St -

Is Benitec Biopharma Limited's (ASX:BLT) Balance Sheet Strong Enough To Weather A Storm?

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Is financial flexibility worth the lower cost of capital. … Debt capital generally has lower cost of capital compared to equity funding

Simply Wall St -

What Kind Of Shareholder Appears On The Benitec Biopharma Limited's (ASX:BLT) Shareholder Register?

A look at the shareholders of Benitec Biopharma Limited (ASX:BLT) can tell us which group is most powerful. … Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … Companies that have been privatized tend to have low insider ownership.

Simply Wall St -

Company Info

Description

Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The company provides BB-301, a single administration ddRNAi-based gene therapy for the treatment of oculopharyngeal muscular dystrophy; and BB-103 ddRNAi-based therapies for the treatment of human hepatitis B. The company was founded in 1995 and is headquartered in Melbourne, Australia.

Details
Name: Benitec Biopharma Limited
BLT
Exchange: ASX
Founded: 1995
A$16,590,559
313,029,426
Website: http://www.benitec.com
Address: Benitec Biopharma Limited
114 William Street,
Level 14,
Melbourne,
Victoria, 3000,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX BLT Ordinary Shares Australian Securities Exchange AU AUD 04. May 2002
OTCPK BNIK.F Ordinary Shares Pink Sheets LLC US USD 04. May 2002
DB BJ9 Ordinary Shares Deutsche Boerse AG DE EUR 04. May 2002
CHIA BLT Ordinary Shares Chi-X Australia AU AUD 04. May 2002
NasdaqCM BNTC SPON ADR EA REPR 20 ORD Nasdaq Capital Market US USD 13. Jul 2012
DB BJ91 SPON ADR EA REPR 20 ORD Deutsche Boerse AG DE EUR 13. Jul 2012
Number of employees
Current staff
Staff numbers
0
Benitec Biopharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/18 10:32
End of day share price update: 2019/11/17 00:00
Last earnings filing: 2019/08/29
Last earnings reported: 2019/06/30
Last annual earnings reported: 2019/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.